decapeptide / C4X Discovery - LARVOL DELTA

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer (clinicaltrials.gov) - P2 | N=84 | Active, not recruiting | Sponsor: Washington University School of Medicine | Trial completion date: Apr 2027 ➔ Aug 2026

Trial completion date • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PIK3CA

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer (clinicaltrials.gov) - P2; N=84; Active, not recruiting; Sponsor: Washington University School of Medicine; Recruiting ➔ Active, not recruiting

Enrollment closed • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PIK3CA

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer (clinicaltrials.gov) - P2; N=87; Recruiting; Sponsor: Washington University School of Medicine; Trial completion date: Apr 2025 ➔ Apr 2027; Trial primary completion date: Dec 2020 ➔ Apr 2022

Clinical • Combination therapy • Trial completion date • Trial primary completion date